Navigation Links
Researchers identify agent responsible for protection against early stages of atherosclerosis
Date:12/12/2011

(Boston) - Researchers from Boston University School of Medicine (BUSM) have identified for the first time the A2b adenosine receptor (A2bAR) as a possible new therapeutic target against atherosclerosis resulting from a diet high in fat and cholesterol. The findings, which appear on-line in Circulation, may have significant public health implications.

Adenosine is a metabolite produced naturally by cells at low levels, and at higher levels during exercise or stress. Adenosine binds to and activates cell surface receptors, one of which is the A2bAR. Previous studies have described the A2bAR as anti-inflammatory and protective against kidney ischemia, cardiac reperfusion injury and restenosis, typically via bone marrow cell signals.

In mouse models, BUSM researchers found atherosclerosis induced by a high-fat diet was more pronounced in the absence of the A2bAR. They also found bone marrow transplantation experiments indicated that A2bAR bone marrow cell signals alone were not sufficient to elicit this effect. "A2bAR genetic ablation led to elevated levels of liver and plasma cholesterol and triglycerides, and to fatty-liver pathology typical of steatosis, assessed by enzymatic assays and analysis of liver sections," explained senior author Katya Ravid, MD, a professor of medicine and biochemistry at BUSM.

The researchers also identified the mechanism underlying this effect in the liver, involving the control of the transcription factor SREBP-1 and its downstream targets-regulators of lipid synthesis. They found restoration of the A2bAR in the liver of A2bAR null mice reduced the lipid profile and atherosclerosis. "Most importantly, in vivo administration of a pharmacological activator of the A2bAR in control mice on a high fat diet reduced lipid profile and atherosclerosis. Thus, this study provides the first evidence that the A2bAR regulates liver hyperlipidemia and atherosclerosis, suggesting that this receptor may be an effective therapeutic target against earlier stages of atherosclerosis," Ravid added.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers use new finding to clear bloodstream malaria infection in mice
2. Penn researchers repair immune system in leukemia patients following chemotherapy
3. Scar findings could lead to new therapies, Stanford researchers say
4. Researchers identify a novel therapeutic approach for liver cancer
5. Researchers design Alzheimers antibodies
6. Toronto researchers obtain detailed molecular signature for Tankyrase
7. Danish mushroom inspires cancer researchers
8. Bone Drugs May Also Battle Breast Cancer, Researchers Say
9. Researchers discover that changes in bioelectric signals cause tadpoles to grow eyes in back, tail
10. UCLA researchers suggest unconventional approach to control HIV epidemics
11. Mayo Clinic researchers find drug duo kills chemotherapy-resistant ovarian cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... CA (PRWEB) , ... April 25, 2017 , ... ... access, support, and collaboration, announces Mirroring360 Pro . This new addition to ... comprehensive collaboration experience for education and business. , Mirroring360 Pro enables educators, business ...
(Date:4/25/2017)... Indianapolis, IN (PRWEB) , ... April 25, 2017 ... ... Washington, D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration ... Life Financial will provide insight into what changes are most likely to make ...
(Date:4/25/2017)... ... April 25, 2017 , ... Patients ... that achieves results in a fraction of the time as traditional braces – ... Significance Dental Specialists, now offers this revolutionary treatment with or without a referral. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the thriving multi-billion ... head shops –can’t help but be heartened by the industry’s current surge. But another ... described as “skunk smell.” At last they can simply, safely and effectively end ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
Breaking Medicine Technology: